Skip to content
BHP

Research peptides in sarcopenia: myostatin, GH-axis, and mitochondrial approaches

Reviewed by the BestHealingPeptides Editorial Team ·

Sarcopenia — age-related loss of skeletal muscle mass and function — affects an estimated 5-13% of adults aged 60-70 and 11-50% of adults over 80, contributing substantially to falls, disability, and mortality in older populations. Pharmacological approaches to sarcopenia remain limited relative to the disease burden, with resistance exercise and adequate protein intake as the mainstay interventions. Peptide research spans three complementary approaches: myostatin-pathway inhibition (follistatin and related compounds), IGF-1/protein synthesis stimulation (IGF-1 LR3), and mitochondrial/exercise-mimetic pharmacology (MOTS-c, tesamorelin GH-axis). Clinical translation across these approaches has been challenging, with functional-endpoint requirements proving difficult to meet consistently.

The recurring pattern across myostatin-pathway clinical development (ACE-083 follistatin-Fc, bimagrumab, and related programmes) has been that anatomical muscle hypertrophy is achievable but the translation to consistent functional-endpoint improvement is challenging — reflecting the multi-factorial nature of muscle function in older and disease populations. This translation-gap remains one of the key open questions in sarcopenia pharmacology and informs continued research on combined pharmacological-plus-exercise-intervention strategies.

Notable finding

Condition background

Sarcopenia is defined by low muscle mass combined with low muscle strength or low physical performance according to consensus criteria (EWGSOP2 in Europe). The condition progresses through age-related mechanisms including reduced satellite cell activity, mitochondrial dysfunction, chronic low-grade inflammation, altered neuromuscular junction function, anabolic resistance (reduced protein-synthetic response to amino acid intake), and reduced physical activity. Consequences include reduced functional capacity, increased falls risk, hospitalisation-associated immobility complications, and increased mortality. Sarcopenic obesity — combining muscle loss with excess adiposity — is a particularly disabling phenotype in older populations. The pharmacological space has historically been small; recent progress in myostatin-pathway pharmacology and metabolic-peptide research has begun to expand the therapeutic toolkit.

Current treatment landscape

Current UK management of sarcopenia is primarily non-pharmacological. Resistance exercise (specifically progressive resistance training) is the highest-efficacy intervention documented for muscle mass and function preservation in older populations, with NHS physiotherapy and community exercise programmes providing access. Adequate protein intake (typically 1.0-1.2 g/kg/day in older adults, higher in acute illness contexts) supports the anabolic response to exercise. Vitamin D supplementation is recommended where deficient. Management of comorbidities that impair mobility and nutrition is important. No pharmacological medication is currently licensed by MHRA specifically for sarcopenia. Off-label use of testosterone in hypogonadal older men is documented in specialist-endocrinology settings with modest muscle-preservation effects. GH replacement in confirmed GH deficiency is a specialist-endocrinology consideration. Bariatric-surgery-associated sarcopenia is a specific clinical scenario receiving increasing pharmacological research attention.

Why peptides are studied here

Three complementary pharmacological approaches to sarcopenia research are represented in the peptide space. The myostatin-inhibition approach exploits the observation that myostatin (GDF-8) is the dominant endogenous negative regulator of muscle mass — myostatin blockade increases muscle mass in animal models and human muscular-dystrophy trials. [Follistatin](/peptides/follistatin) binds and sequesters myostatin (and related TGF-β family ligands), providing pharmacological muscle-hypertrophy potential; ACE-083 (follistatin-Fc fusion) progressed through Phase II trials in Duchenne muscular dystrophy and FSHD with mixed results. The IGF-1/protein-synthesis approach uses [IGF-1 LR3](/peptides/igf-1-lr3) — a recombinant IGF-1 analogue with extended half-life — to drive IGF-1R-mediated satellite cell activation and myoblast proliferation; grey-market IGF-1 LR3 use in strength-sport communities has documented substantial (though safety-uncharacterised) muscle-hypertrophy effects. The mitochondrial/exercise-mimetic approach engages [MOTS-c](/peptides/mots-c) — a mitochondrial-derived peptide activating AMPK with exercise-mimetic effects on muscle endurance and metabolic function. The GH-axis approach uses [tesamorelin](/peptides/tesamorelin), a GHRH analogue driving endogenous GH release with downstream IGF-1 elevation; tesamorelin is FDA-licensed for HIV-associated lipodystrophy rather than sarcopenia specifically but the mechanistic overlap is relevant. Clinical translation across all these approaches has been challenging, with functional-endpoint requirements (six-minute walk, timed function tests) proving difficult to meet consistently despite anatomical hypertrophy.

Relevant research peptides

Notable study findings

  • Follistatin (ACE-083 Phase II)

    ACE-083 (follistatin-Fc fusion) achieved intramuscular hypertrophy in Phase II trials for Duchenne muscular dystrophy and FSHD but functional endpoints (six-minute walk, timed function tests) did not consistently reach registrable improvement thresholds. Development did not progress to Phase III — a recurring theme across myostatin-axis clinical translation.

  • IGF-1 LR3 (pre-clinical)

    Pre-clinical satellite-cell activation and myoblast-proliferation studies with IGF-1 LR3 demonstrate the compound's mechanistic capacity to drive muscle protein synthesis through IRS-1/PI3K/Akt signalling. Clinical characterisation in sarcopenia specifically is limited; grey-market use in strength-sport communities has documented substantial hypertrophy effects with substantial safety uncertainty.

  • MOTS-c (exercise-mimetic)

    MOTS-c administration in aged mice produces AMPK activation, improved muscle endurance, and improved metabolic flexibility — supporting the mitochondrial-peptide exercise-mimetic framework potentially relevant to sarcopenia, though clinical characterisation in aged human populations remains limited.

  • Bimagrumab (comparative)

    Bimagrumab (a myostatin-antibody rather than follistatin-derived compound) explored the same mechanistic space through Phase III sarcopenia development with mixed results; the compound was subsequently repositioned for obesity development. The bimagrumab clinical trajectory illustrates the challenge of defining registrable sarcopenia endpoints across the myostatin-pathway class.

UK regulatory notes

None of the peptides referenced on this page are MHRA-licensed for sarcopenia. Follistatin, IGF-1 LR3, and MOTS-c are research compounds not licensed as medicines in any jurisdiction. Tesamorelin (Egrifta) is FDA-licensed for HIV-associated lipodystrophy but not sarcopenia; MHRA licensing is limited. All these compounds fall within WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — MOTS-c specifically was added to the Prohibited List following characterisation of exercise-endurance effects. Research use in appropriate laboratory contexts is not restricted by UK medicines law; supply for human use engages the Human Medicines Regulations 2012.

Frequently asked questions

What is sarcopenia?
Sarcopenia is age-related loss of skeletal muscle mass and function, defined by low muscle mass combined with low muscle strength or low physical performance (EWGSOP2 European consensus criteria). It affects approximately 5-13% of adults aged 60-70 and 11-50% of adults over 80, contributing substantially to falls, disability, and mortality risk.
Why is exercise still the mainstay treatment despite pharmacological research progress?
Progressive resistance training remains the highest-efficacy intervention for muscle mass and function preservation in older populations, with substantial evidence base and negligible adverse-event profile. Pharmacological interventions can produce anatomical muscle hypertrophy but translation to consistent functional improvement (walking speed, strength endurance, activities of daily living) has proven challenging. Exercise is expected to remain foundational even as pharmacological adjuncts develop.
Why has myostatin-pathway pharmacology not delivered licensed sarcopenia medications yet?
The recurring clinical-development pattern — including ACE-083 (follistatin-Fc), bimagrumab (myostatin antibody), and related programmes — has been that anatomical hypertrophy is achievable but functional endpoints (six-minute walk, timed function tests) do not consistently reach registrable improvement thresholds. This anatomical-versus-functional disconnect is characteristic and reflects the multi-factorial nature of muscle function in older populations.
Is IGF-1 LR3 a viable sarcopenia treatment?
IGF-1 LR3 is a research compound with substantial pre-clinical muscle-hypertrophy activity and grey-market use in strength-sport communities documenting anatomical hypertrophy in athletic populations. Formal clinical characterisation in sarcopenia populations is absent; substantial safety uncertainty exists particularly for the oncogenic-risk considerations of chronic IGF-1R activation. The compound is not licensed as a medicine and clinical use in older sarcopenia populations is not appropriate outside carefully designed early-clinical research.
How does MOTS-c differ from other sarcopenia-relevant peptides?
MOTS-c is a mitochondrial-derived peptide activating AMPK with metabolic-regulatory and exercise-mimetic effects. Its mechanistic focus is mitochondrial-metabolic rather than direct anabolic (unlike IGF-1 LR3) or myostatin-pathway (unlike follistatin). The exercise-mimetic framework is potentially relevant to sarcopenia given the exercise-response-attenuation ('anabolic resistance') characteristic of aging muscle, but clinical characterisation in older populations remains limited.
Is there any licensed pharmacological treatment for sarcopenia in the UK?
No — no MHRA-licensed medication currently exists specifically for sarcopenia. Off-label use of testosterone in hypogonadal older men is documented in specialist settings with modest muscle-preservation effects. GH replacement in confirmed GH deficiency is a specialist consideration. Vitamin D supplementation where deficient supports muscle function. Otherwise, pharmacological options are limited to clinical-trial participation.
What is sarcopenic obesity?
Sarcopenic obesity is the combination of low muscle mass with excess adiposity — a particularly disabling phenotype in older populations that combines the mobility and functional consequences of sarcopenia with the metabolic and joint consequences of obesity. Modern incretin weight-loss therapy (semaglutide, tirzepatide, retatrutide) requires specific consideration in this population given the risk of accelerated lean-mass loss alongside adipose-mass loss; combined incretin-plus-resistance-exercise strategies are an active research area.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.